Enzo study could lead to clinical diagnostic for IPF, 2/14

Create PDF

“The significance of this discovery, beyond providing a reliable marker for screening and diagnosis, is the potential for development of new therapeutic strategies and better understanding of the progression of the disease in humans,” Elazar Rabbani, study co-author and chief executive officer of Enzo, said in a statement. “This may also translate into a patient’s ability to live with the disease or even be cured if the fibrosis is not too advanced.”

Enzo Biochem, 212-532-3232